Literature DB >> 31753040

Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition.

Benjamin Fourneaux1,2, Aurélien Bourdon2, Bérengère Dadone3, Carlo Lucchesi2, Scott R Daigle4, Elodie Richard1,2, Audrey Laroche-Clary1,2, François Le Loarer5, Antoine Italiano6,7.   

Abstract

The Editor-in-Chief would like to alert readers that the ownership of some of the data presented in this article [1].

Entities:  

Year:  2019        PMID: 31753040      PMCID: PMC6873665          DOI: 10.1186/s13045-019-0825-3

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


Correction to: J Hematol Oncol. 2019 12:11 https://doi.org/10.1186/s13045-018-0694-1 The Editor-in-Chief would like to alert readers that the ownership of some of the data presented in this article [1] is currently under dispute. Specifically, the data in Fig. 1b is under dispute by the PI of the ICGC leiomyosarcoma program and L’Institut Bergonie. The PI of the ICGC leiomyosarcoma program has stated the authors did not have permission to use the data presented in Fig. 1b. The Board of the French Sarcoma Group, which responded to concerns from the PI of the ICGC leiomyosarcoma program, has also requested that either Fig. 1b be removed or the paper should be retracted. However, L’Institut Bergonie has stated the authors had the right to use the data and that the data were collected at the institution. Pending further institutional investigation of these concerns, further editorial action may be taken. Aurélien Bourdon, Carlo Lucchesi, Elodie Richard, Audrey Laroche-Clary, François Le Loarer, and Antoine Italiano agree to this Expression of Concern. Benjamin Fourneaux, Bérengère Dadone, and Scott R. Daigle have not responded to any correspondence from the editor or publisher about this Expression of Concern.
  1 in total

1.  Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition.

Authors:  Benjamin Fourneaux; Aurélien Bourdon; Bérengère Dadone; Carlo Lucchesi; Scott R Daigle; Elodie Richard; Audrey Laroche-Clary; François Le Loarer; Antoine Italiano
Journal:  J Hematol Oncol       Date:  2019-01-25       Impact factor: 17.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.